Buprenorphine naloxone

Drugs

Volumn 69, Issue 5, 2009, Pages 577-607

  Orman, Jennifer S ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; CLONIDINE; DELAVIRDINE; DEXTROPROPOXYPHENE PLUS PARACETAMOL; DIAMORPHINE; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; METHADONE; MORPHINE; MU OPIATE RECEPTOR; NELFINAVIR; OPIATE; OPIATE AGONIST; PLACEBO; RITONAVIR; BUPRENORPHINE; NALOXONE; NARCOTIC ANTAGONIST;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY DISORDER; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BINDING AFFINITY; CELLULITIS; CHILL; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG USE; DRUG WITHDRAWAL; FLUSHING; HEADACHE; HOSPITAL PATIENT; HUMAN; HYPERTENSION; INFECTION; INJECTION; INJECTION SITE ABSCESS; INSOMNIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG EDEMA; LUNG TUMOR; MAINTENANCE THERAPY; NAUSEA; OPEN STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; OUTPATIENT; OUTPATIENT DEPARTMENT; PATIENT SATISFACTION; PHARMACODYNAMICS; PHYSIOLOGY; POPULATION; PRESCRIPTION; QT INTERVAL; RECOMMENDED DRUG DOSE; REVIEW; RHINITIS; SHOULDER INFECTION; SIDE EFFECT; STOMACH PAIN; SUICIDAL BEHAVIOR; SWEATING; THERAPY EFFECT; TRAFFIC ACCIDENT; TREATMENT OUTCOME; URINALYSIS; VASODILATATION; VOMITING; WEAKNESS; WITHDRAWAL SYNDROME; DRUG COMBINATION; DRUG INTERACTION;

BUPRENORPHINE; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; DRUG INTERACTIONS; HUMANS; METHADONE; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS;

EID: 64949102344     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969050-00006     Document Type: Review

References (107)

1. US Department of Health and Human Services. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: a treament improvement protocol TIP 40 [online]. Available from URL: http://www.naabt.org/ links/TIP-40-PDF.pdf [Accessed 2007 Mar 1]
2. Best SE, Oliveto AH, Kosten TR. Opioid addiction: recent advances in detoxification and maintenance therapy. CNS Drugs 1996 Oct; 6 (4): 301-14
3. National Institute on Drug Abuse. Principles of drug ad- diction treatment: a research-based guide [online]. Available from URL: http://www.drugabuse.gov/PODAT/ PODATIndex.html [Accessed 2007 Jun 18]
4. Srivastava A, Kahan M. Buprenorphine: a potencial new treatment option for opioid dependence. CMAJ 2006 Jun 20; 174(13): 1835-6
5. McCance-Katz EF. Office-based buprenorphine treatment for opioid-dependent patients. Harv Rev Psychiatry 2004 Nov/Dec; 12 (6): 321-38
6. Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003 Apr 22; (2): CD002207
7. Goldman FR, Thistel CI. Diversion of methadone: illicit methadone use among applicants to two metropolitan drug abuse programs. Int J Addict 1978 Aug; 13 (6): 855-62
8. Sullivan LE, Chawarski M, O'Connor PG, et al. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend 2005 Jul; 79 (1): 113-6
9. Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007 Apr 17; 88 (1): 75-8
10. Chapleo CB, Walter DS. The buprenorphine-naloxone combination product. Res Clin Forums 1997; 19 (2): 55-8
11. European Medicines Agency. Scientific discussion (Suboxone) [online]. Available from URL: http://www.emea.europa. eu/humandocs/PDFs/EPAR/suboxone/ 069706en6.pdf [Accessed 2007 Jan 4]
12. Mégarbane B, Hreiche R, Pirnay S, et al. Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol Rev 2006; 25 (2): 79-85
13. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978 Apr; 35 (4): 501-16
14. Wesson DR. Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S. J Psychoactive Drugs 2004 May; Suppl. 2: 119-28
15. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994 May; 55 (5): 569-80
16. Ciraulo DA, Hitzemann RJ, Somoza E, et al. Pharmaco-kinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. J Clin Pharmacol 2006; 46: 179-92
17. Greenwald MK, Johanson C-E, Moody DE, et al. Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsycho-pharmacology 2003 Nov; 28 (11): 2000-9
18. Zubieta J-K, Greenwald MK, Lombardi U, et al. Bupre-norphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology 2000; 23 (3): 326-34
19. Umbricht A, Huestis MA, Cone EJ, et al. Effects of high-dose intravenous buprenorphine in experienced opioid abusers. J Clin Psychopharmacol 2004 Oct; 24 (5): 479-87
20. Bickel WK, Stitzer ML, Bigelow GE, et al. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 1988 Oct; 247 (1): 47-53
21. Lintzeris N, Mitchell TB, Bond A, et al. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. J Clin Psychopharmacol 2006 Jun; 26 (3): 274-83
22. Walsh SL, June HL, Schuh KJ, et al. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl) 1995; 119 (3): 268-76
23. European Medicines Agency. Suboxone: summary of product characteristics [online]. Available from URL: http:// www.emea.europa.eu/humandocs/PDFs/EPAR/ suboxone/ H-697-PI-en.pdf [Accessed 2009 Feb 11]
24. Eissenberg T, Greenwald MK, Johnson RE, et al. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther 1996; 276 (2): 449-59
25. Bliesener N, Albrecht S, Schwager A, et al. Plasma testosterone and sexual function in men receiving buprenor-phine maintenance for opioid dependence. J Clin Endocrinol Metab 2005 Jan; 90 (1): 203-6
26. Hallinan R, Byrne A, Agho K, et al. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med 2008 Mar; 5 (3): 684-92
27. Soyka M, Lieb M, Kagerer S, et al. Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial. J Clin Psychopharmacol 2008 Dec; 28 (6): 699-703
28. Wedam EF, Bigelow GE, Johnson RE, et al. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007 Dec 10/24; 167 (22): 2469-75
29. Fanoe S, Hvidt C, Ege P, et al. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart 2007 Sep; 93 (9): 1051-5
30. Endo Laboratories. Narcan® (naloxone hydrochloride injection) label [online]. Available from URL: http:// www.fda.gov [Accessed 2007 Jan 30]
31. Loimer N, Hofmann P, Chaudry HR. Nasal administration of naloxone is as effective as the intravenous route in opiate addicts. Int J Addict 1994; 29 (6): 819-27
32. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend 2003; 70: S59-77
33. Robinson GM, Dukes PD, Robinson BJ, et al. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend 1993 Jun; 33 (1): 81-6
34. Robinson SE. Buprenorphine-containing treatments: place in the management of opioid addiction. CNS Drugs 2006; 20 (9): 697-712
35. Fudala PJ, Yu E, Macfadden W, et al. Effects of bupre-norphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 1998 Mar 1; 50: 1-8
36. Mendelson J, Jones RT, Fernandez I, et al. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin Pharmacol Ther 1996 Jul; 60 (1): 105-14
37. Bigelow GE, Preston KL, Liebson IA. Abuse liability assessment of buprenorphine-naloxone combinations. NIDA Res Monogr 1987; 76: 145-9
38. Mendelson J, Jones RT, Welm S, et al. Buprenorphine and naloxone interactions in methadone maintenance patients. Biol Psychiatry 1997 Jun 1; 41 (11): 1095-101
39. Mendelson J, Jones RT, Welm S, et al. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berl) 1999 Jan; 141 (1): 37-46
40. Harris DS, Jones RT, Welm S, et al. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000 Dec 22; 61 (1): 85-94
41. Preston KL, Bigelow GE, Liebson IA. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berl) 1988; 94 (4): 484-90
42. Stoller KB, Bigelow GE, Walsh SL, et al. Effects of bu-prenorphine/ naloxone in opioid-dependent humans. Psychopharmacology (Berl) 2001 Mar; 154 (3): 230-42
43. Reckitt Benckiser Pharmaceuticals, Inc. Suboxone (buprenor-phine HC1 and naloxone HC1 dihydrate sublingual tablets)/ Subutex (buprenorphine HC1 sublingual tablets): US prescribing information [online]. Available from URL: http:// www.suboxone.com/patients/pi/ [Accessed 2009 Feb 11]
44. Strain EC, Walsh SL, Bigelow GE. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology (Berl) 2002 Jan 1; 159 (2): 161-6
45. Comer SD, Walker EA, Collins ED. Buprenorphi-ne/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology (Berl) 2005 Oct; 181 (4): 664-75
46. Correia CJ, Walsh SL, Bigelow GE, et al. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. Psychopharmacology (Berl) 2006 Sep 30; 189 (3): 297-306
47. Rosado J, Walsh SL, Bigelow GE, et al. Sublingual bu-prenorphine/naloxone precipitated withdrawal in subjects maintained on 100 mg of daily methadone. Drug Alcohol Depend 2007 Oct 8; 90 (2): 261-9
48. Weinhold LL, Preston KL, Farre M, et al. Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug Alcohol Depend 1992 Aug; 30 (3): 263-74
49. Mintzer MZ, Correia CJ, Strain EC. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. Drug Alcohol Depend 2004 May 10; 74 (2): 205-9
50. Rapeli P, Fabritius C, Alho H, et al. Methadone vs. bu-prenorphine/ naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol 2007 Jun 12; 7: 5
51. Baker JR, Best AM, Pade PA, et al. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother 2006 Mar; 40 (3): 392-6
52. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003 May 21; 70 Suppl. 2: S39-47
53. Elkader A, Sproule B. Buprenorphine: clinical pharmaco-kinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005; 44 (7): 661-80
54. Compton P, Ling W, Chiang N, et al. Pharmacokinetics of buprenorphine: a comparison of sublingual tablet versus liquid after chronic dosing. J Addict Med 2007 Jun; 1 (2): 88-95
55. Center for Drug Evaluation and Research. Clinical phar-macology and biopharmaceutics reviews: application number: 20-732, 20-733 (Suboxone®) [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2002/ 20-733-Subutex-BioPharmr.pdf [Accessed 2007 Feb 8]
56. Harris DS, Mendelson JE, Lin ET, et al. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin Pharmacokinet 2004; 43 (5): 329-40
57. Pérez de los Cobos J, Martin S, Etcheberrigaray A, et al. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. Drug Alcohol Depend 2000 Jun 1; 59 (3): 223-33
58. McCance-Katz EF, Moody DE, Morse GD, et al. Interactions between buprenorphine and antiretrovirals: I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis 2006 Dec 15; 43 Suppl. 4: S224-34
59. McCance-Katz EF, Moody DE, Smith PF, et al. Interactions between buprenorphine and antiretrovirals: II. The protease inhibitors nelfmavir, lopinavir/ritonavir, and ri-tonavir. Clin Infect Dis 2006 Dec 15; 43 Suppl. 4: S235-46
60. McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ ritonavir. Drug Alcohol Depend 2007 Dec 1; 91 (2-3): 269-78
61. Strain EC, Stitzer ML, Liebson IA, et al. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am I Psychiatry 1994 Jul; 151 (7): 1025-30
62. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992 May 27; 267 (20): 2750-5
63. Johnson RE, Chutuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000 Nov 2; 343 (18): 1290-7
64. Johnson RE, Eissenberg T, Stitzer ML, et al. A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995; 40 (1): 17-25
65. Vigezzi P, Guglielmino L, Marzorati P, et al. Multimodal drug addiction treatment: a field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients. I Subst Abuse Treat 2006; 31 (3): 3-7
66. Mattick RP, Ali R, White JM, et al. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98 (4): 441-52
67. Ling W, Charuvastra C, Collins IF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998; 93 (4): 475-86
68. Schottenfeld RS, Chawarski MC, Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet 2008 Jun 28; 371 (9631): 2192-200
69. Cheskin LJ, Fudala PJ, Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend 1994; 36 (2): 115-21
70. O'Connor PG, Carroll KM, Shi JM, et al. Three methods of opioid detoxification in a primary care setting: a randomized trial. Ann Intern Med 1997 Oct 1; 127 (7): 526-30
71. Seifert I, Metzner C, Paetzold W, et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone. Pharmacopsychiatry 2002; 35 (5): 159-64
72. Janiri L, Mannelli P, Persico AM, et al. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend 1994; 36 (2): 139-45
73. Bell I, Byron G, Gibson A, et al. A pilot study of bupre-norphine- naloxone combination tablet (Suboxone®) in treatment of opioid dependence. Drug Alcohol Rev 2004 Sep;23(3):311-7
74. Fudala PI, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl I Med 2003 Sep 4; 349 (10): 949-58
75. Kamien JB, Branstetter SA, Amass LA. Buprenorphine-nalox-one versus methadone maintenance therapy: a randomized double-blind trial with opioid dependent patients. Heroin Addict Relat Clin Probl 2008; 10 (4): 5-18
76. Kakko J, Grönbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007 May; 164 (5): 797-803
77. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006 Jul 27; 355 (4): 365-74
78. Amass L, Kamien JB, Mikulich SK. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 2001 Jan 1; 61 (2): 173-81
79. Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend 2000 Feb 1;58 (1-2): 143-52
80. Bell J, Shanahan M, Mutch C, et al. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 2007 Dec; 102 (12): 1899-907
81. Mintzer IL, Eisenberg M, Terra M, et al. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007 Mar-Apr; 5 (2): 146-50
82. Cunningham C, Giovanniello A, Sacajiu G, et al. Buprenorphine treatment in an urban community health center: what to expect. Fam Med 2008 Jul-Aug; 40 (7): 500-6
83. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
84. Sullivan LE, Moore BA, Chawarski MC, et al. Buprenor-phine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat 2008 Jul; 35 (1): 87-92
85. Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict 2008 Mar-Apr; 17 (2): 116-20
86. Amass L, Ling W, Freese TE, et al. Bringing buprenor-phine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict 2004; 13 Suppl. 1: S42-66
87. Ling W, Amass L, Shoptaw S, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005 Aug; 100(8): 1090-100
88. Ziedonis DM, Amass L, Steinberg ML, et al. Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug Alcohol Depend 2009 Jan 1; 99 (1-3): 28-36
89. NIDA/SAMHSA. Short term opioid withdrawal using bupre-norphine [online]. Available from URL: https://casat.unr.edu/mwattc/docs/Detox-Trainer-Guide.pdf [Accessed 2007 Jan 4]
90. Ling W, Hillhouse M, Domier C, et al. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009 Feb; 104 (2): 256-65
91. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 2008 Nov 5; 300 (17): 2003-11
92. Brigham GS, Amass L, Winhusen T, et al. Using buprenorphine short-term taper to facilitate early treatment engagement. J Subst Abuse Treat 2007 Jun; 32 (4): 349-56
93. Renzelli CM, Capretto NA. Less pain, more gain: buprenorphine-naloxone and patient retention in treatment. J Addict Dis 2006; 25 (3): 97-104
94. Collins ED, Horton T, Reinke K, et al. Using buprenor-phine to facilitate entry into residential therapeutic community rehabilitation. J Subst Abuse Treat 2007 Mar; 32 (2): 167-75
95. Drugs and Poisons Regulation Group. Policy for maintenance pharmacotherapy for opioid dependence [online]. Available from URL: http://www.health.vic.gov.au/dpu/downloads/poilicy-opioid.pdf [Accessed 2006 Dec 8]
96. Vocci FJ, Acri J, Elkashef A. Medication development for addictive disorders: the state of the science. Am J Psychiatry 2005 Aug; 162 (8): 1432-40
97. Ling W, Cunningham-Rathner J, Rawson R. Diffusion of substance abuse treatment: will buprenorphine be a success? J Psychoactive Drugs 2004 May; Suppl. 2: 115-7
98. Nielsen S, Dietze P, Lee N, et al. Concurrent buprenor-phine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction 2007 Apr; 102 (4): 616-22
99. Gerra G, Borella F, Zaimovic A, et al. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 2004 Jul 15; 75 (1): 37-45
100. Gerra G, Leonardi C, D'Amore A, et al. Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: a retrospective study. Prog Neuropsycho-pharmacol Biol Psychiatry 2006 Mar; 30 (2): 265-72
101. Simojoki K, Vorma H, Alho H. A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Subst Abuse Treat Prev Policy 2008 Jun 17; 3: 16
102. Gowing L, Ali R, White J. Buprenorphine for the man-agement of opioid withdrawal. Cochrane Database Syst Rev 2006 Apr 19; (2): CD002025
103. Fiellin DA. Treatment of adolescent opioid dependence: no quick fix. JAMA 2008 Nov 5; 300 (17): 2057-9
104. Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci 2007; 9 (4): 455-70
105. Doran CM. Buprenorphine, buprenorphine/naloxone and methadone maintenance: a cost-effectiveness analysis. Expert Rev Pharmacoeconomics Outcomes Res 2005; 5 (5): 583-91
106. Raisch DW, Fudala PJ, Saxon AJ, et al. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/naloxone to patients with opioid dependence. J Am Pharm Assoc 2005 Jan-Feb; 45 (1): 23-32
107. Finch JW, Kamien JB, Amass LA. Two-year experience with buprenorphine/naloxone (Suboxone) for maintenance treatment of opioid dependence within a private practice setting. J Addic Med 2007 Jun; 1 (2): 104-10